Acumen Pharmaceuticals, Inc.
ABOS
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 46.94% | -72.29% | |||
| Gross Profit | -46.94% | 72.29% | |||
| SG&A Expenses | -9.38% | 1.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.47% | -23.30% | |||
| Operating Income | -37.47% | 23.30% | |||
| Income Before Tax | -42.21% | 22.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.21% | 22.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.21% | 22.50% | |||
| EBIT | -37.47% | 23.30% | |||
| EBITDA | -37.49% | 23.31% | |||
| EPS Basic | -42.08% | 23.06% | |||
| Normalized Basic EPS | -42.06% | 23.05% | |||
| EPS Diluted | -42.08% | 23.06% | |||
| Normalized Diluted EPS | -42.06% | 23.05% | |||
| Average Basic Shares Outstanding | 0.08% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||